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ABSTRACT
Background. Cytotoxic therapy for relapsed and refractory
germ cell tumors or metastatic sex cord stromal tumors is rarely
effective and is often accompanied by high adverse event rates.
Expression of CD30 has been observed in testicular cancers,
and patients with CD30-expressing embryonal carcinomas have
worse progression-free survival and overall survival than those
with CD30-negative tumors. The objective of this study
(NCT01461538) was to characterize the antitumor activity of
brentuximab vedotin in patients with CD30-expressing nonlym-
phomatous malignancies. Enrolled patients included seven
patients with relapsed or refractory germ cell tumors or meta-
static sex cord stromal tumors described in this case series.
Materials and Methods. Forty patients with relapsed or refrac-
tory germ cell tumors, metastatic sex cord stromal tumors, or
testicular tumors were screened for CD30 expression; 14
patients had tumors that expressed CD30. Seven patients with
CD30-expressing testicular cancer were enrolled in the treat-
ment study: ﬁve patients with germ cell tumors, one patient
with a Leydig cell tumor, and one patient with a Sertoli cell
tumor. Patients were treated with brentuximab vedotin at ini-
tial doses of 1.8 or 2.4 mg/kg every 3 weeks. Response assess-
ments were performed at cycles 2 and 4 and every 4 cycles
thereafter while the patient was receiving treatment.
Results. Two of seven patients achieved an objective response,
including one durable complete response and one partial
response at a single time point. Both responding patients had
germ cell tumors. Treatment with brentuximab vedotin was
generally well tolerated.
Conclusion. Treatment of relapsed or refractory germ cell
tumors with brentuximab vedotin can induce durable
responses with a manageable toxicity proﬁle. The Oncologist
2018;23:316–323
Implications for Practice: This case series of seven patients with relapsed or refractory CD30-expressing germ cell tumors (GCTs) or
sex cord stromal tumors demonstrates that brentuximab vedotin has activity against GCTs and is well tolerated in heavily pretreated
patients with these aggressive tumor types. One patient achieved a complete response that has been durable for almost 4 years
since the discontinuation of treatment with brentuximab vedotin. Therefore, brentuximab vedotin may be a valuable option for
physicians who care for this difﬁcult-to-treat patient population.
INTRODUCTION
Testicular cancer is the most common solid tumor among men
aged 15–44 years [1]. Testicular cancers are classiﬁed as germ
cell tumors (GCTs) or non-germ cell tumors, with sex cord stro-
mal tumors (SCSTs) comprising the majority of the latter cate-
gory. Rarely, GCTs are present solely in extragonadal sites, such
as the anterior mediastinum or retroperitoneum. The histology
of GCTs is divided into seminomas and nonseminomatous
GCTs (NSGCTs), and NSGCTs can be further subdivided into
embryonal carcinomas (ECs), teratomas, yolk sac tumors, and
choriocarcinomas. Germ cell tumors are extremely sensitive to
cisplatin-based chemotherapy compared with other solid
tumors, and more than 70% of patients with GCTs are cured
with initial cisplatin-based chemotherapy with or without
adjunctive surgery [2–4]. Among patients with GCTs in whom
initial treatment is not successful, salvage treatments, includ-
ing chemotherapy (conventional or high-dose) or additional
surgeries, have increased the survival rate [5, 6]. Independent
risk factors that indicate a worse prognosis in patients treated
Correspondence: Costantine Albany, M.D., Indiana University Division of Hematology and Oncology, 535 Barnhill Drive, Indianapolis, Indiana
46202, USA. Telephone: 317-944-0920; e-mail: calbany@iu.edu Received October 17, 2017; accepted for publication October 24, 2017;
published Online First on December 8, 2017. http://dx.doi.org/10.1634/theoncologist.2017-0544
TheOncologist 2018;23:316–323 www.TheOncologist.com Oc AlphaMed Press 2017
Genitourinary Cancer
with high-dose salvage chemotherapy include platinum-
refractory disease, persistent disease following two or more
lines of prior chemotherapy, and a high-risk International
Germ Cell Cancer Collaborative Group (IGCCCG) stage at the
time of initial treatment [7]. Individuals who relapse following
treatment with high-dose salvage chemotherapy (HDCT) have
an especially dire prognosis, with a long-term survival rate of
<5% [8].
Available treatment options for patients with multiply
relapsed disease include gemcitabine, oxaliplatin, oral etoposide,
paclitaxel, or additional salvage surgeries [2, 5]. However, these
treatments rarely lead to durable disease remissions and are
often accompanied by high adverse event rates [7, 9]. A recent
retrospective analysis of patients with relapsed or refractory
GCT treated with a range of therapies across several phase II tri-
als demonstrated a low objective response rate (ORR; 1%) and a
median overall progression-free survival of only 1 month [5].
Sex cord stromal tumors (Sertoli and Leydig cell tumors) are
usually benign. However, approximately 10% of tumors in
adults are malignant and can metastasize and ultimately lead
to death [10]. Patients with metastatic Sertoli and Leydig cell
tumors also currently face limited treatment options. Radiation
and chemotherapy are usually not effective in the presence of
metastatic disease, and surgical resection is therefore the rec-
ommended treatment option. Orchiectomy may be followed
by retroperitoneal lymph node dissection if there is evidence of
regional lymph node metastasis or if high-risk features are iden-
tiﬁed within the primary tumor [10, 11].
Expression of CD30 has been observed in a number of non-
lymphomatous malignancies, including testicular cancer. Specif-
ically, EC, which is present in approximately 90% of NSGCTs [12]
either alone or, more commonly, in conjunction with other his-
tologies as part of a mixed cell GCT, has been shown to express
high levels of CD30, whereas other GCTs do not express CD30
[13]. Additionally, CD30 is not expressed in normal adult, neo-
natal, or fetal testicular tissue, suggesting that therapies target-
ing CD30 may be useful in the treatment of certain subtypes of
testicular cancer. A recent examination of CD30 expression as a
prognostic indicator in patients with relapsed or refractory EC
demonstrated that patients with CD30-expressing tumors had
worse progression-free survival and overall survival than
patients with CD30-negative tumors. Moreover, serial biopsy
results demonstrated that CD30 expression was persistent in
tumors after relapse, further highlighting its potential useful-
ness as a therapeutic target [14].
Brentuximab vedotin (Adcetris, Seattle Genetics, Inc.,
Bothell, WA) is an anti-CD30 antibody-drug conjugate (ADC)
consisting of the chimeric anti-CD30 monoclonal IgG1 antibody
(cAC10), speciﬁc to human CD30, covalently attached to the
microtubule-disrupting agent monomethyl auristatin E
(MMAE) by a protease-cleavable linker. The ADC binds to CD30-
expressing cells, leading to internalization of the ADC-CD30
complex and the release of MMAE via proteolytic cleavage
within the cell. Binding of MMAE to tubulin disrupts the micro-
tubule network within the cell, inducing cell cycle arrest and
apoptotic death of the cell [15]. Targeted delivery of MMAE to
CD30-expressing cells is the primary mechanism of action of
brentuximab vedotin [16]; however, additional proposed mech-
anisms of tumor cell killing that may contribute to the clinical
activity of brentuximab vedotin include antibody-dependent
cellular phagocytosis, immunogenic cell death, and the
bystander effect [17–23].
Two pivotal phase II studies have demonstrated the efﬁcacy
and safety of brentuximab vedotin administered every 3 weeks
(Q3W) as a single agent for treating relapsed or refractory
Hodgkin lymphoma (HL) and systemic anaplastic large cell lym-
phoma (ALCL), both of which express high levels of CD30. The
ORR for patients with HL was 75%, with approximately one
third of patients achieving a complete remission (CR) [24]. An
ORR of 86% was observed in patients with systemic ALCL, with
over 50% of patients achieving a CR [25]. In both studies, bren-
tuximab vedotin was generally well tolerated with manageable
side effects.
A phase II, open-label study to evaluate the antitumor
activity, safety, pharmacokinetics, and immunogenicity of
brentuximab vedotin in patients with CD30-expressing non-
lymphomatous malignancies (NCT01461538) was sponsored
by Seattle Genetics, Inc. Seven patients with CD30-expressing
GCTs and SCSTs (four patients with testicular GCTs, one patient
with an anterior mediastinal GCT, one patient with a Sertoli
cell tumor, and one patient with a Leydig cell tumor) were
enrolled in the treatment study and were administered
brentuximab vedotin at starting doses of either 1.8 mg/kg or
2.4 mg/kg Q3W. The outcomes of these seven patients are
presented in this case series.
MATERIALS AND METHODS
Patients
Patients with CD30-expressing nonlymphomatous tumors were
identiﬁed through a companion screening protocol that
employed immunohistochemical staining (IHC) of tissue biopsy
samples using an anti-BerH2 antibody [26]. Patients with histo-
logically conﬁrmed CD30-expressing tumors (10% CD30
expression) must have also failed, refused, or have been
deemed ineligible for standard therapy. Patients must have had
measurable disease, deﬁned for solid tumors as at least one
nonresectable lesion10 mm in the longest diameter. Patients
were required to be at least 12 years of age (or6 years of age
with permission from the sponsor) and have an Eastern Coop-
erative Oncology Group Performance Status score of 0 or 1 or a
Karnofsky or Lansky Performance Status score 70. Screening
and treatment studies were performed at investigational sites
following approval by an investigational review board (IRB),
and all patients provided informed consent prior to administra-
tion of any study treatment. Institutional review board
oversight for the seven patients described in this study report
was performed by the Indiana University IRB (IRB study
#1111007468) and the U.S. Oncology IRB (Protocol #10328).
Study Design and Treatment
During the screening study, CD30 expression was assessed in
eligible patients with GCTs, SCSTs, unclassiﬁed sex cord tumors,
and unclassiﬁed testicular tumors. Seven patients with CD30-
expressing disease were subsequently enrolled in the treat-
ment study from May 2012 to February 2014 and were treated
with brentuximab vedotin administered via intravenous infu-
sion over a period of 30 minutes on day 1 of each 21-day cycle.
Patients enrolled under the original protocol received an initial
dose of 1.8 mg/kg Q3W (Cohort 1), the recommended single-
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agent dose for the treatment of relapsed or refractory HL and
systemic ALCL. However, the original phase I dose escalation
study of brentuximab vedotin in hematological malignancies
(NCT00430846) demonstrated acceptable toxicity up to a dose
level of 2.7 mg/kg Q3W. Therefore, after completion of enroll-
ment of Cohort 1 in this study, the protocol was amended to
evaluate a second cohort of patients dosed with 2.4 mg/kg
brentuximab vedotin Q3W. Following enactment of the amend-
ment, patients who were initially treated with 1.8 mg/kg bren-
tuximab vedotin Q3W (Cohort 1) and were still on-study could
also have their dose increased to 2.4 mg/kg Q3W at the discre-
tion of the investigator. Dose reductions for tolerability were
allowed during the course of the study. Response assessments
were performed at cycles 2 and 4 and every four cycles there-
after while the patient was receiving treatment. Efﬁcacy assess-
ments included radiographic tumor imaging of the chest,
abdomen, and pelvis graded using Response Evaluation Criteria
in Solid Tumors version 1.1 [27]. Patients with stable disease or
better were eligible to continue treatment with brentuximab
vedotin until disease progression, unacceptable toxicity, or
study closure. In addition, physical examination, serum
chemistry panels, coagulation panels, complete blood counts
with differential, performance status, and select vital sign
measurements were performed on day 1 of each cycle. Patients
were monitored for unacceptable toxicities. Adverse events
were recorded for the safety reporting period from day 1
predose through the end of treatment visit or 30 days after the
last study treatment, whichever was later.
Chart Review
This study was not speciﬁcally designed to evaluate patients
with GCTs or SCSTs; rather, it was designed to evaluate patients
with a broad range of nonlymphomatous lesions. Therefore,
chart reviews were conducted by the investigators to collect
relevant clinical testicular cancer information that may not
have been collected as part of the study. The results of this
chart review in concert with data collected during the original
study are presented for each of the seven patients with CD30-
expressing GCTs and SCSTs who were treated with brentuximab
vedotin.
RESULTS
A total of 40 patients with GCTs, SCSTs, unclassiﬁed sex cord
tumors, and unclassiﬁed testicular tumors were screened for
CD30 expression by IHC. Of these, 14 patients were considered
to have CD30-expressing tumors, using a cutoff for positivity of
10% staining by IHC. Seven patients (ﬁve patients with GCTs,
one patient with a Leydig cell tumor, and one patient with a
Sertoli cell tumor) with CD30-expressing disease were subse-
quently enrolled in the treatment study. In total, two patients
achieved an objective response, including one complete
response and one partial response at a single time point, the
former of which is ongoing. Additionally, three patients
achieved a best response of stable disease (Fig. 1).
Case 1
A 24-year-old male patient initially presented with a poor-risk,
metastatic, mixed testicular GCT (60% embryonal cell and 40%
choriocarcinoma). He had lung, liver, and brain metastases; ret-
roperitoneal disease; and a human chorionic gonadotropin
(HCG) level >180,000 mIU/mL. The patient underwent a left
radical orchiectomy, a left suboccipital craniotomy, and gamma
knife radiation treatment to the cerebellum. Frontline chemo-
therapy included three cycles of bleomycin, etoposide, and cis-
platin (BEP) and one cycle of etoposide and cisplatin (EP). He
subsequently relapsed with pulmonary disease and was treated
with one cycle of paclitaxel and gemcitabine, followed by a
HDCT regimen consisting of two cycles of carboplatin plus eto-
poside with autologous stem cell rescue and radiation therapy
to the right hilum. After relapsing again, he received additional
salvage therapy with four cycles of gemcitabine, oxaliplatin,
and paclitaxel. After achieving a best response of stable disease,
his disease progressed 5 months later. At that point his archived
orchiectomy tumor specimen was evaluated for CD30 expres-
sion, which was found to be present in 90% of tumor cells, and
he was enrolled in the treatment study.
At baseline staging, the patient’s HCG was 5,571 mIU/mL,
and he had target lesions on the spleen, periaortic lymph node,
right lobe of the lung, and right iliacus muscle (Table 1). The
patient began treatment with brentuximab vedotin 1.8 mg/kg
Q3W. His HCG decreased to 1,924 mIU/mL after the ﬁrst cycle
of treatment and further decreased to 45 mIU/mL after the
second treatment cycle. Cycle 2 response assessments indi-
cated a partial response to therapy. After two additional cycles
of brentuximab vedotin, he experienced an increase in HCG to
502 mIU/mL and a further increase to 4,076 mIU/mL after the
fourth cycle. At that point a computed tomography (CT) scan
also showed evidence of disease progression at multiple sites.
No additional therapy was given, and the patient subsequently
died of progressive disease approximately 8 months after com-
ing off the study.
Case 2
A 33-year-old male patient presented with a poor-risk, meta-
static, mixed testicular GCT consisting of EC, choriocarcinoma,
and teratoma. He initially presented with an enlarged left
supraclavicular lymph node, large bilateral pulmonary metasta-
ses, retroperitoneal disease, and a tumor in his right testis. The
patient’s HCG was 133,161 mIU/mL. Frontline treatment
included four cycles of etoposide, ifosfamide, and cisplatin
Figure 1. Best responses in patients with testicular cancer treated
with brentuximab vedotin. Swimmer’s plot showing the best
response and duration of response in all patients with testicular
cancer treated with brentuximab vedotin. Solid bars represent
time on treatment, and hatched bars represent time off treatment.
Time of progression is noted by a black arrow, onset of partial
responses by a brown diamond, onset of complete responses by a
gray diamond, and time of death by a purple hexagon. The patient
in Case 1 achieved a partial response at a single time point only.
Abbreviations: CR, complete remission; PD, progressive disease;
PR, partial response; SD, stable disease.
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(VIP). Prior to the start of therapy, a biopsy of his left supracla-
vicular lymph node revealed 75% EC, 20% choriocarcinoma,
and 5% mature teratoma. After completing four cycles of VIP,
he underwent a delayed orchiectomy that revealed only mature
teratoma. He then relapsed with his HCG increased, and he was
found to have a new brain metastasis that was treated with ste-
reotactic radiosurgery, with complete disappearance of his
tumor. He was then treated with an HDCT regimen of carbopla-
tin and etoposide, followed by an autologous stem cell trans-
plant. Stable disease was achieved for 1 month, after which the
patient’s disease progressed. At that point, his left supraclavic-
ular lymph node sample was evaluated for CD30 expression
and was found to have 90% of malignant cells stain positive for
CD30 by IHC. He was then enrolled in the treatment study.
At the baseline visit, the patient’s HCG was 10,401 mIU/mL.
Lesions were present in a left supraclavicular lymph node, right
and left upper lungs, and a left retroperitoneal lymph node
(Table 1). The patient began receiving brentuximab vedotin at a
dose of 1.8 mg/kg Q3W. His HCG decreased to 832 mIU/mL fol-
lowing the ﬁrst treatment cycle, decreased further to 111 mIU/
mL following the second cycle, and reached a nadir of 53 mIU/
mL after the third treatment cycle. Tumor assessments follow-
ing cycle 2 indicated stable disease with no progression of tar-
get lesions and no new nontarget lesions. Following the fourth
treatment cycle, the patient’s HCG increased to 439 mIU/mL,
but radiologically he continued to have stable disease. After
cycle 5 of brentuximab vedotin, the patient’s HCG had
increased to 1,186 mIU/mL, and his left lung lesion had
increased in size. New lesions were also present in the liver and
lung. The patient was considered to have progressive disease
and discontinued treatment with brentuximab vedotin. The
patient subsequently died of progressive disease less than 2
months after coming off the study.
Case 3
A 58-year-old male patient was diagnosed with a metastatic
pure EC with good risk per the IGCCCG criteria. He underwent
a left radical orchiectomy followed by four cycles of BEP at an
outside institution and achieved stable disease. He relapsed
with metastatic disease in the retroperitoneal lymph nodes and
was treated with a HDCT regimen of two cycles of carboplatin
and etoposide and tandem autologous stem cell transplant. He
achieved stable disease but relapsed after 7 months with liver
and mesenteric metastases, at which time he received oral eto-
poside. A duodenal mass sample was evaluated for CD30
expression and was determined to be 100% CD30-positive. He
then enrolled in the treatment study.
At baseline, the patient had two lesions on the liver, a mes-
enteric mass on the small intestine (Table 1), and HCG and
alpha-fetoprotein (AFP) within the normal range. The patient
Table 1. Clinical features of patients with germ cell tumors or sex cord stromal tumors treated with brentuximab vedotin
Patient Tumor type
Sites of metastasis
at enrollment
Best
response
CD30
expression H-score
CD30 cellular
localization
HCG:
mIU/mL
AFP:
ng/mL
1 Mixed GCT: EC,
choriocarcinoma
Spleen, lung, iliacus
muscle, periaortic
lymph nodes
Partial
responsea
90% 190 Membrane,
cytoplasm
BL 5,571.0,
min 45.3
(C3D1)
N
2 Mixed GCT: EC,
choriocarcinoma,
teratoma
Lung,
supraclavicular
lymph nodes,
retroperitoneal
lymph nodes
Stable
disease
90% 195 Membrane,
cytoplasm
BL 1,0401.0,
min 52.7
(C4D1)
BL 3.1,
min 2.5
(C5D1)
3 EC Liver, mesentery/
small intestine,
retroperitoneum
Progressive
disease
100% 265 Membrane,
cytoplasm,
Golgi
BL 1.3 BL 2.9
4 Mixed GCTb: EC,
seminoma,
teratoma
Lung; mediastinal,
hilar, and
supraclavicular
lymph nodes
Complete
response
100% 270 Membrane,
cytoplasm,
Golgi
N N
5 Primary
mediastinal GCT
Mediastinum,
carina, aortic arch,
lung, lytic bone
lesions
Progressive
disease
80% 230 Membrane,
cytoplasm
N BL 151.5,
min 151.5
(BL)
6 Sertoli cell Lung;
supraclavicular,
subcarinal, and
paratracheal lymph
nodes
Stable
disease
98% 206 Membrane,
cytoplasm
N N
7 Leydig cell Lung;
supraclavicular,
subcarinal, and
retrocrural lymph
nodes; pelvis
Stable
disease
100% 225 Membrane,
cytoplasm
N N
H-score (range 0–300) was calculated as the product of the intensity of CD30 staining (0–3) multiplied by the percentage of positively staining cells
(0–100).
aThis patient achieved a partial response at a single time point only.
bMetastatic disease displayed pure EC histology.
Abbreviations: AFP, alpha-fetoprotein; BL, baseline value; C, cycle; D, day; EC, embryonal carcinoma; GCT, germ cell tumor; H-score, histo score;
HCG, human chorionic gonadotropin; min, minimum on-study value; N, normal or not performed.
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received one cycle of brentuximab vedotin at a dose of 1.8 mg/
kg but experienced multiple adverse events and subsequently
discontinued treatment. At the end of treatment visit, the
patient’s imaging studies showed unequivocal progression of
nontarget lesions in the liver. The patient subsequently had
rapid deterioration and died of progressive disease 2 months
after coming off the study.
Case 4
A 26-year-old male patient initially presented with a right testis
mass and underwent a right radical orchiectomy. Tumor pathol-
ogy demonstrated a mixed GCT composed of 90% EC and
smaller components of seminoma and teratoma. On staging,
he was found to have metastatic disease involving the lungs
and retroperitoneal, mediastinal, and left supraclavicular lymph
nodes. Tumor markers were normal. For good risk, stage III-A,
mixed NSGCT, he received four cycles of EP and achieved a par-
tial response with normalization of his tumor markers but had
residual retroperitoneal nodes and small remaining lung nod-
ules. Although a retroperitoneal lymph node dissection demon-
strated no evidence of viable disease, shortly thereafter he was
found to have enlarging mediastinal lymph nodes and lung
nodules without elevated tumor markers. Viable EC was dem-
onstrated on a thoracoscopic biopsy specimen. The patient was
treated with HDCT using a regimen of paclitaxel and ifosfamide
followed by carboplatin and etoposide, including three cycles
of high-dose carboplatin and etoposide, each followed by stem
cell reinfusion. He achieved a near complete response and was
again placed on surveillance. However, approximately 5 months
later, he was noted to have enlarging right lower lobe lung nod-
ules and underwent a right lower lobectomy and regional
lymph node dissection, with pathology demonstrating viable
EC in both right lower lobe lung nodules as well as intralobular
lymph nodes. On active surveillance, the patient developed
progression in the lungs and mediastinal lymph nodes approxi-
mately 2 months later. He was enrolled in a phase II clinical trial
of 5-ﬂuorouracil, oxaliplatin, and leucovorin plus alvocidib (ﬂa-
vopiridol, Tolero Pharmaceuticals, Inc.) but progressed after
two cycles. A lung tumor sample from the patient’s thoracot-
omy was evaluated for CD30 expression by IHC and was found
to be 100% CD30-positive. He was subsequently enrolled in the
treatment study.
At baseline, the patient had lesions on the medial, lower
right lobe of the lung and on the inferior hilum of the right lung
(Table 1). Nontarget lesions were also present in supraclavicular
and mediastinal lymph nodes. The patient began receiving
brentuximab vedotin at a dose of 1.8 mg/kg Q3W. He achieved
a partial response after two cycles, with the right lung lesion
completely resolving and the right hilar lesion decreasing in
size, and converted to a complete response after four cycles
(Fig. 2). The patient continued treatment with brentuximab
vedotin 1.8 mg/kg Q3W, and a complete response to treatment
was maintained through the cycle 12 response assessment (Fig.
2). After 14 cycles of therapy, he began experiencing progres-
sive lower extremity weakness, with difﬁculty climbing stairs
and pain in his posterior calves. On examination, he was noted
to have lower extremity weakness, including decreased
strength in bilateral ankle plantar and dorsiﬂexion and hypore-
ﬂexia of the knees and ankles. Strength in the wrist extensors
bilaterally was more subtly decreased. Peripheral sensory and
motor neuropathy events, including those observed in this
patient, are known side effects of treatment with brentuximab
vedotin [28]. Given these symptoms and ﬁndings, cycle 15 was
not administered and the patient was subsequently placed on
close monitoring. As of his last follow-up, complete response
has been maintained without evidence of disease at more than
46 months from his last dose of brentuximab vedotin and over
55 months from study enrollment. He has had near complete
resolution of weakness in his hands with signiﬁcant improve-
ment in strength in his lower extremities.
Case 5
A 28-year-old male patient was diagnosed with an anterior
mediastinal GCT composed of 95% EC and 5% seminoma/yolk
sac tumor. He received frontline therapy of four cycles of BEP
and achieved a partial response, after which his disease
relapsed in the anterior mediastinum and subcarinal lymph
nodes. He then received one cycle of paclitaxel, cisplatin, and
ifosfamide. The patient’s mediastinal tumor was assessed for
CD30 expression and was found to be 80% CD30-positive by
IHC.The patient subsequently enrolled in the treatment study.
At baseline, he had disease in his mediastinum, carina, and
aortic arch (Table 1), and his AFP was elevated at 152 ng/mL.
The patient received one cycle of 2.4 mg/kg brentuximab vedo-
tin but began experiencing symptomatic deterioration 1 week
after the ﬁrst dose and subsequently discontinued treatment.
The patient died of progressive disease approximately 5
months after discontinuing the study drug.
Case 6
A 32-year-old male patient presented with a diagnosis of stage
I seminoma. The patient underwent a radical right orchiectomy
with adjuvant radiation to the right iliac and periaortic lymph
nodes, after which he remained disease-free for approximately
2.5 years. He then relapsed radiographically in an interaorto-
caval lymph node and was treated with three cycles of BEP,
followed by retroperitoneal and right iliac lymph node dissec-
tions, spermatic cord excision, and retroperitoneal mass exci-
sion. Pathology revealed residual GCT with a question of EC
and seminoma elements. Subsequently, he had no evidence of
disease for approximately 19 months, at which point a chest
x-ray demonstrated new bilateral pulmonary metastases. The
patient received one cycle of VIP and sought further medical
attention for consideration of a tandem transplant. At that
time, the previous pathology specimens were re-examined and
the patient’s tumor was determined to be a Sertoli cell tumor
and not a seminoma as originally diagnosed. He underwent
two cycles of paclitaxel and gemcitabine and a thoracotomy
with wedge resection of pulmonary metastases, but his disease
progressed. The patient was subsequently enrolled in a clinical
trial of the gamma secretase (Notch) inhibitor MK-0752, which
he discontinued because of an adverse event.The patient’s tho-
racotomy sample was evaluated for CD30 expression and was
found to be 98% CD30-positive by IHC. He was then enrolled in
the treatment study.
At baseline, the patient had target lesions on the subcarinal
lymph node, the paratracheal lymph node, the lower lobes of
the right and left lungs, and the left supraclavicular lymph node
(Table 1). The patient initiated treatment with 1.8 mg/kg bren-
tuximab vedotin Q3W and received four cycles of treatment.
He achieved stable disease after two cycles of treatment, but
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all lesions showed evidence of progression at the cycle 4
assessment visit. Treatment with brentuximab vedotin was
then discontinued, and the patient died 9 months later from
progressive disease.
Case 7
A 61-year-old male patient was diagnosed with a stage I, 3.8-cm,
metastatic Leydig cell tumor that was treated with a left orchiec-
tomy. The patient remained disease-free for approximately 2
years following surgery, at which time an abdominal CT scan
revealed extensive retroperitoneal adenopathy and several small
bilateral pulmonary metastases. The patient underwent a retro-
peritoneal lymph node dissection, left nephrectomy, and partial
thoracotomy, which revealed 21 lymph nodes involved with a
metastatic Leydig cell tumor. Several lung nodules were also
removed, with pathology demonstrating involvement by the
Leydig cell tumor. Immunohistochemistry revealed 100% expres-
sion of CD30 in the tumor in his kidney and lymph node
samples. The patient had stable disease for approximately 2
months, after which his disease progressed and he was enrolled
into the treatment study.
At baseline, lesions were present in a subcarinal lymph
node, a supraclavicular lymph node, upper and lower lobes of
the right lung, and the pelvis (Table 1). The patient initiated
treatment with brentuximab vedotin at a dose of 1.8 mg/kg
Q3W. After two cycles of treatment, the patient achieved stable
disease, which was maintained at the cycle 4 assessment. The
patient’s cycle 5 and cycle 6 doses of brentuximab vedotin
were increased to 2.4 mg/kg Q3Was a result of the approval of
a protocol amendment to test the safety and efﬁcacy of this
higher dose level. His stable disease was maintained through
six cycles of treatment, at which point he experienced progres-
sion of a cough and fatigue and the onset of shortness of
breath. The patient opted to withdraw from the study because
symptomatic deterioration and subsequently died of progres-
sive disease 1 month after coming off the trial.
Figure 2. Treatment with brentuximab vedotin induced a complete response in a patient (Case 4) with a germ cell tumor. Computed
tomography scans over time of a right lung nodule (A), second right lung nodule (B), and mediastinal lymph node (C) in the patient in
Case 4 who was treated with 1.8 mg/kg brentuximab vedotin. After cycle 2, the patient achieved a partial response that converted into a
durable complete response after cycle 4.
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DISCUSSION
In this case series, seven patients with relapsed or refractory
CD30-expressing GCTs or SCSTs were treated with brentuximab
vedotin at starting doses of 1.8 mg/kg or 2.4 mg/kg. One
patient (Case 4) achieved a complete response after four cycles
of treatment with brentuximab vedotin that has been main-
tained for more than 46 months since discontinuation of ther-
apy following cycle 14. One patient (Case 1) achieved a partial
response to treatment at a single time point following two
cycles of treatment with brentuximab vedotin but discontinued
after four cycles of treatment because of progressive disease.
Three patients (Cases 2, 6, and 7) also achieved stable disease
that was maintained for up to six cycles of treatment, whereas
two patients (Cases 3 and 5) had a best response of progressive
disease.
Germ cell tumors that are refractory to multiple courses of
chemotherapy, including high-dose treatment with stem cell
rescue, historically have a low rate of response to many single
and combination chemotherapeutic regimens [2, 9, 29]. In a
retrospective study examining the outcomes of 90 patients
with relapsed or refractory GCTs enrolled in seven single-agent,
phase II trials, no patients achieved a complete response, 1
patient (1%) achieved a partial response, and 15 patients (17%)
achieved stable disease [5]. In an additional trial, the single-
agent mesenchymal-epithelial transition (c-MET) inhibitor
tivantinib did not demonstrate any activity in patients with
relapsed or refractory GCTs, with no patients achieving com-
plete or partial response [30]. Therefore, the objective
responses seen in two of the ﬁve patients with GCTs in this
study indicate that brentuximab vedotin may have signiﬁcant
clinical activity in this difﬁcult-to-treat patient population.
Brentuximab vedotin is an ADC that targets CD30-
expressing cells. Patients with a variety of non-Hodgkin lympho-
mas exhibiting CD30 expression levels 10% have responded
to treatment with brentuximab vedotin in clinical trials [17,
31–33]. Preclinical evidence suggests that even in mixed histol-
ogy tumors, cells lacking CD30 are susceptible to treatment if
they are in close proximity to CD30-expressing cells [22]. Collec-
tively, these data suggest that tumor CD30 expression levels
may vary widely while still responding to treatment with bren-
tuximab vedotin and support the rationale for selection of a
10% CD30 expression level for inclusion in the current study.
The most widely recognized extralymphoid expression of
CD30 is in EC, and the presence of CD30 has been correlated
with the presence of EC in mixed GCTs [14]. Additionally, CD30
expression has been shown to be retained in patients with met-
astatic GCTs even after multiple chemotherapeutic regimens
[14], and has been identiﬁed as a prognostic factor for meta-
static disease, suggesting that CD30 is a promising target for
therapy in relapsed or refractory GCTs. In this subset of refrac-
tory GCTs, the patient in Case 4 who achieved a durable com-
plete response had a mixed GCT in the testis with metastatic
disease consisting entirely of EC. Thoracic metastases removed
after HDCT demonstrated very strong 31 IHC staining for CD30
(80%), which was observed at the cell membrane as well as dif-
fusely in the cytoplasm and in the Golgi. However, high levels
of CD30 expression did not appear to correlate with response
to treatment in all patients (Table 1), and a patient with a pure
EC (Case 3) did not achieve a response. The lack of response in
many patients with high levels of CD30 in this study may be
due to acquired or intrinsic resistance to brentuximab vedotin.
The cellular mechanisms of resistance to brentuximab vedotin
are not well characterized, but elucidating these mechanisms is
an active area of research. Data from studies in brentuximab
vedotin-resistant cell lines have offered insight into global cellu-
lar changes following treatment, with potential mechanisms of
resistance including loss of CD30 expression and overexpres-
sion of the multi-drug resistance 1 (MDR1) drug exporter [34].
The relative signiﬁcance of these in vitro mechanisms as they
relate to clinical isolates is still being evaluated.
As this study was exploratory in nature, only a limited num-
ber of patients with GCTs or SCSTs were enrolled. Although two
of ﬁve patients with GCTs achieved objective responses, addi-
tional studies in larger patient cohorts will be required to deter-
mine the clinical activity of brentuximab vedotin in relapsed or
refractory GCT. Additionally, studies examining the use of bren-
tuximab vedotin in both CD30-expressing and CD30-negative
tumors in patients with relapsed or refractory GCTs and SCSTs
will help to further elucidate the role of CD30 in these diseases.
A phase II, open-label efﬁcacy study further examining the use
of brentuximab vedotin in relapsed or refractory GCTs, spon-
sored by Seattle Genetics, Inc. (NCT02689219), is currently
underway. Further studies are also required to determine
whether brentuximab vedotin may be useful in combination
therapy with other active agents that do not share an overlap-
ping toxicology proﬁle.
CONCLUSION
This case series demonstrates the activity of brentuximab vedo-
tin in a small cohort of seven patients with relapsed or refrac-
tory CD30-expressing GCTs or SCSTs, including one patient who
achieved a durable complete response that remains ongoing
more than 46 months after discontinuation of treatment.
Therefore, brentuximab vedotin may be a treatment option in
this particularly aggressive disease.
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